ASCO 2024
Advertisement
The results may establish osimertinib as the new standard of care for EGFR-mutated NSCLC in a certain setting.
Dr. Paz-Ares shares his insights on recent studies and highlights practice-changing data in lung cancer.
Experts weigh in on the long-term results presented at the 2024 American Society of Clinical Oncology Annual Meeting.
The panel discusses key questions about NSCLC treatment regimens and the research that could answer them.
Experts discuss important management considerations and the importance of working with a multidisciplinary team.
A panel of experts shares their insights on key developments and advances in lung cancer treatment research.
An expert panel discusses treatment and quality-of-life considerations, as well as what to do while awaiting NGS results.
The panel discusses combination therapies and treatment considerations for patients without targetable mutations.
Experts weigh in on unmet needs and what clinicians should consider when treating patients who lack driver mutations.
Experts weigh in on NSCLC screening and diagnostic challenges and the prevalence of metastatic disease at diagnosis.
Researchers say the results support the evaluation of the treatment in the phase 3 CodeBreaK 202 trial.
Study investigators say that extended follow-up research on nivolumab consolidation is essential.
Dr. Paz-Ares shares his insights on the study's results and the remaining questions about ADCs in lung cancer treatment.
The CheckMate 9LA study evaluated first-line nivolumab plus ipilimumab with 2 cycles of platinum-doublet chemotherapy.
Researchers compared outcomes between patients with baseline stage III N2 and non-N2 NSCLC.
Researchers assessed patients' functional health and well-being across multiple physical and mental domains.
Study investigators say the results support further study of the bispecific T-cell engager in previously treated SCLC.
Laila Gharzai, MD, discusses her research on the financial impacts of lung biomarker testing.
Narjust Florez, MD, FASCO, discusses her research on the unique needs of young patients with lung cancer.
Most patients who received adjuvant osimertinib achieved MRD negativity.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.